Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer

A phase II trial in metastatic breast cancer (MBC) (NO16853) failed to show noninferiority (progression-free survival, PFS) of capecitabine 825 mg/m(2) plus docetaxel 75 mg/m(2) to the registered capecitabine dose of 1,250 mg/m(2) plus docetaxel 75 mg/m(2). We developed a modeling framework based on...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Bruno, R, Lindbom, L, Schaedeli Stark, F, Chanu, P, Gilberg, F, Frey, N, Claret, L
格式: Artigo
語言:Inglês
出版: Nature Publishing Group 2012
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3600724/
https://ncbi.nlm.nih.gov/pubmed/23835839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/psp.2012.20
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍